EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Concordance between ER, PR, Ki67, and HER2‐low expression in breast cancer by MammaTyper RT‐qPCR and immunohistochemistry: implications for the practising pathologist

Nahla M Badr iD, Mohamed Zaakouk, Qi Zhang, Daniel Kearns, Anthony Kong, Abeer M Shaaban

Histopathology · 2024

DOI: 10.1111/his.15193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2024. Verfasst von Nahla M Badr und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Ki-67 Antigen, Immunohistochemistry. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biontech Diagnostic GmbH, Egyptian Cultural and Educational Bureau, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are limited data on the role of multigene tests and their correlation with immunohistochemistry (IHC), especially on core biopsy. MammaTyper is a quantitative conformite Europeeanne (CE) marked, National Institute for Health and Care excellence (NICE) approved, in in vitro diagnostic quantitative real‐time polymerase chain reaction (RT‐qPCR) test for assessment of mRNA expression of four biomarkers ( ESR1 , PGR , ERBB2 , MKI67 ).

Methods

We evaluated the concordance of MammaTyper with oestrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 by IHC on 133 core needle biopsies of breast cancer. HER2 was positive if IHC 3+ or 2+ and fluorescence in situ hybridization (FISH)‐amplified. Global and hotspot Ki67 expression was analysed using a cutoff of ≥20% assessed manually and by digital image analysis. Agreements were expressed as overall percent agreement (OPA), positive percent agreement (PPA), negative percent agreement (NPA), and Cohen's kappa.

Results

RT‐qPCR results of ESR1 were highly concordant with IHC with OPA of 94.7% using 1% cutoff and 91.7% when the low ER‐positive category was included. The PPA and NPA between RT‐qPCR and IHC for PR was 91.5% and 88.0%, respectively, when using the 1% cutoff. For ERBB2 /HER2, the OPA was 95% and the PPA was 84.6%. 40 of 72 HER2 IHC score 0 tumours were classified as ERBB2 low. Best concordance between MKI67 by MammaTyper and Ki67 IHC was achieved using hotspot digital image analysis (OPA: 87.2%, PPA: 90.6%, NPA: 80%).

Conclusion

RT‐qPCR‐based assessment of the mRNA expression of ESR1 , PGR , ERBB2 , and MKI67 showed high concordance with IHC, suggesting that the MammaTyper test on core needle biopsies represents a reliable, efficient, and reproducible alternative for breast cancer classification and refining HER2 low categorisation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesKi-67 AntigenImmunohistochemistryBiomarkers, TumorReceptors, ProgesteroneReal-Time Polymerase Chain ReactionReceptors, EstrogenHumansFemaleBiopsy, Large-Core NeedleAdultMiddle AgedIn Situ Hybridization, Fluorescence

Stichwörter der Autor:innen

HER2HER2‐lowKi67breast canceroestrogen receptorprogesterone receptor

Substanzen

Erb-b2 Receptor Tyrosine KinasesKi-67 AntigenBiomarkers, TumorReceptors, ProgesteroneReceptors, EstrogenERBB2 protein, humanMKI67 protein, human

Autor:innen und Institutionen

  • Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Department of Pathology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt.
  • Cancer Pathology Department, National Cancer Institute, Cairo University, Giza, Egypt.
  • Shuwen Biotech Co. Ltd., Hangzhou, Zhejiang Province, China.
  • Queen Elizabeth Hospital Birmingham, Birmingham, UK.
  • King's College London, London, UK.

ORCID-Profile: Nahla M Badr

Förderung

  • Biontech Diagnostic GmbH
  • Egyptian Cultural and Educational Bureau
  • Cancer Research UK

Zitieren

APA

Badr, N. M., Zaakouk, M., Zhang, Q., Kearns, D., Kong, A., & Shaaban, A. M. (2024). Concordance between ER, PR, Ki67, and HER2‐low expression in breast cancer by MammaTyper RT‐qPCR and immunohistochemistry: implications for the practising pathologist. Histopathology. https://doi.org/10.1111/his.15193

Vancouver

Badr NM, Zaakouk M, Zhang Q, Kearns D, Kong A, Shaaban AM. Concordance between ER, PR, Ki67, and HER2‐low expression in breast cancer by MammaTyper RT‐qPCR and immunohistochemistry: implications for the practising pathologist. Histopathology. 2024. doi:10.1111/his.15193

BibTeX
@article{Badr2024,
  author = {Badr, Nahla M and Zaakouk, Mohamed and Zhang, Qi and Kearns, Daniel and Kong, Anthony and Shaaban, Abeer M},
  title = {Concordance between ER, PR, Ki67, and HER2‐low expression in breast cancer by MammaTyper RT‐qPCR and immunohistochemistry: implications for the practising pathologist},
  journal = {Histopathology},
  year = {2024},
  doi = {10.1111/his.15193}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche